Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study

Aim of investigation. HEP3002 is the international early access program of efficacy and safety estimation of telaprevir in combination to peginterferon alpha and ribavirin for patients with severe fibrosis or liver cirrhosis caused by hepatitis C virus (HCV) genotype 1. Efficacy and safety of this t...

Full description

Saved in:
Bibliographic Details
Main Authors: D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo
Format: Article
Language:Russian
Published: Gastro LLC 2014-07-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
hcv-infection
telaprevir
pegilated interferon
ribavirin
anemia
rash
early access program
Online Access:https://www.gastro-j.ru/jour/article/view/1089
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.gastro-j.ru/jour/article/view/1089

Similar Items